4,5-Dimethoxy-1-Cyanobenzocyclobutaneum CAS 35202-54-1 Puritas >99.0%
Ruifu Chemical Supple Ivabradine Hydrochloride media Cum High puritate
Ivabradine Hydrochloride CAS 148849-67-6
4,5-Dimethoxy-1-Cyanobenzocyclobutaneum CAS 35202-54-1
(1S)-4,5-Dimethoxy-1-[(methylamino)methyl]benzocyclobutaneum hydrochloridum CAS 866783-13-3
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one CAS 73942-87-7
7,8-Dimethoxy-3-(3-iodopropyl)-1,3-dihydro-2H-3-benzazepin-2-one CAS 148870-57-9
3-(3-Chloropropyl)-7,8-dimethoxy-1H-3-benzazepin-2(3H)-one CAS 85175-59-3
Nomen chemicum | 4,5-Dimethoxy-1-Cyanobenzocyclobutane |
Synonyma | 4,5-Dimethoxy-1-Benzocyclobutenecarbonitrile;1-Cyano-4,5-Dimethoxybenzocyclobutene;3,4-Dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-Carbonitrile;Ivabradine Hydrochloride media |
CAS Number | 35202-54-1 |
CATTUS Number | RF-PI1809 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C11H11NO2 |
M. Pondus | 189.21 |
Liquescens punctum | 83.0~84.0℃ |
Density | 1.18 |
Solubilitas (Solubile in) | Methanol |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Off-White ad lux Brown pulveris |
Lepidium sativum | HPLC/UV obsequium |
Puritas / Analysis Methodus | >99.0% (HPLC) |
Damnum in Siccatio | <0.50% (sicco ad 40℃ usque ad constantem pondus) |
Residere in Ignition | <0.10% |
Substantiae cognatae | |
Individual Impurity | <0.50% |
Totalis immunditias | <1.00% |
Metalla gravis | <10ppm |
Test Standard | Enterprise Standard |
Consuetudinem | Intermedia Ivabradine Hydrochloridis (CAS: 148849-67-6) |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
4,5-Dimethoxy-1-Cyanobenzocyclobutanum (CAS: 35202-54-1) medium est hydrochloridi Ivabradini (CAS: 148849-67-6).Ivabradine hydrochloride quasi certae inhibitoris venae per contactum cum f-canalibus in plasmatis membranae latere intracellulare evolvit.Ac per hoc Ivabradine celeritatem diastolicae depolarizationis minuit et rate cor minuit.Probatum est ad anginas firmas chronicas curandas et viabile optionem praebet aegris contraindicationem vel intolerantia obstructorum b.Aestimatio etiam comparata potentiali curationis ischemicae morbi cordis est.